Dr. Michael Bonham Joins BioAI's Executive Team
Dr. Bonham joins as chief pathologist and executive medical director.
BioAI Health, a biotech company focused on the development of AI/SciML-driven predictive testing to improve cancer treatment and outcomes, announced the addition of Michael Bonham MD, PhD to the growing BioAI executive team, where he will be joining as chief pathologist and executive medical director. Dr. Bonham will oversee all of BioAI's pharma-sponsored digital biomarker programs and help expand the company's growing pathology network.
"We're thrilled to have Dr. Bonham join our team to support our expanding digital biomarkers business," said Thomas Colarusso, CEO and Cofounder at BioAI. "He brings a wealth of knowledge and expertise in developing novel molecular diagnostic tests and digital pathology applications in Oncology."
New machine-learning approach could speed precision drug development
The approach, detailed this week in the journal Nature, uses a platform called Molecular Surface Interaction Fingerprinting (MaSIF) to design custom proteins that bind to drug-bound target proteins.
AI-enabled CGM app shows promise for glycemic control, weight management
The broader implications of this study suggest that digital health platforms like January V2 have the potential to play a crucial role in the future of chronic disease management,” the authors write.
